Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2019

View Archived Issues

Bispecific CD80-IgG4 Fc-IL2V fusion protein shows antitumor activity

Encouraging first-in-human data seen with respiratory syncytial virus vaccine PF-06928316

FDA accepts IND application for EC-5026 for the treatment of pain

First patient dosed in phase I study of ALD-1910

Frequency Therapeutics initiates dosing in phase IIa study of FX-322

Preliminary data presented from phase II study of nivolumab plus ipilimumab in MCC

Discovery and characterization of second-generation HIF-2alpha inhibitor PT-2977

SCR-2682 demonstrates promising activity in rodent MES-induced seizure models

Heterozygous mouse model of VWD associated with dominant-negative mutations

N1,N12-Diacetylspermine: a potential urinary biomarker to monitor tuberculosis treatment

Chinese researchers patent IDO1 inhibitors

Dual voltage-gated calcium channel and mu-opioid receptor ligands revealed in Esteve patent

SiteOne Therapeutics wins grant to support development of lead candidate for postoperative pain

Yuhan identifies AOC3 inhibitors

Takeda synthesizes new hSTING agonists

Aurigene Discovery Technologies describes PRMT5 inhibitors

Potent new small-molecule inhibitors block apoptosis in mice

NIH gives grant to Oligomerix to develop inhibitors of tau olgomer formation

MGB Biopharma completes first cohort in phase IIa study of MGB-BP-3 in CDAD

Kangpu completes first-in-human study of KPG-818

OSE Immunotherapeutics' bispecific anti-PD-1/IL-7 fusion molecule tested in vitro and in vivo

Aerpio releases phase Ib interim data on topical ocular formulation of AKB-9778

PanOptica reports phase I/II topline data on PAN-90806 for wet AMD

Aruna Bio receives support for preclinical development of AB-126

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...